Outcome after transplantation of accelerated-phase vs chronic-phase myelofibrosis. Estimated 5-year overall survival was 65% (95% CI, 49% to 81%) for the accelerated-phase group vs 64% (59% to 69%) for the chronic-phase group (P = .91). Relapse-free survival was 49% (32% to 67%) vs 55% (50% to 61%; P = .65). Median relapse-free survival was 4.8 years for the accelerated-phase group. Estimated 5-year nonrelapse mortality was 20% (8% to 33%) vs 30% (24% to 35%; P = .25), and 5-year incidence of relapse was 30% (14% to 46%) vs 15% (11% to 19%; P = .02).